Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Mortality
[69] Systematic review	4061 people with COPD 3 RCTs in this analysis	Mortality 1 to 3 years 196/2022 (10%) with fluticasone plus salmeterol 249/2029 (12%) with fluticasone	OR 0.76 95% CI 0.62 to 0.93 P = 0.0072	Small effect size	fluticasone plus salmeterol
[69] Systematic review	917 people with COPD 3 RCTs in this analysis	Mortality 1 year 11/462 (2.4%) with budesonide plus formoterol 11/455 (2.4%) with budesonide	OR 0.98 95% CI 0.42 to 2.29 P = 0.96		Not significant
[66] RCT 6-armed trial	1704 people with COPD	Mortality 6 months 3/277 (1.1%) with budesonide 160 micrograms plus formoterol 4.5 micrograms in one metered-dose inhaler twice daily 4/281 (1.4%) with budesonide 80 micrograms plus formoterol 4.5 micrograms in one metered-dose inhaler twice daily 0/287 (0.0%) with budesonide 160 micrograms plus formoterol 4.5 micrograms in separate metered-dose inhalers twice daily 2/275 (0.7%) with budesonide 160 micrograms twice daily	Significance not assessed